Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06485544 | Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial | recruiting | Phase 2 | 104 | Tang-Du HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06475209 | Adebrelimab + Apatinib in SCLC Maintenance Therapy | recruiting | Phase 2 | 60 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT05532696 |
| recruiting |
| Phase 1 / Phase 2 |
| 61 |
| Anbogen Therapeutics, Inc.INDUSTRY |
| 1 |
| Jun 24, 2024 |
| clinicaltrials |
| NCT06110572 | Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation(TESSERACT) | recruiting | Phase 1 / Phase 2 | 18 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06371482 | Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) | recruiting | Phase 2 | 58 | Hebei Medical University Fourth HospitalOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT05284539 | Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer(Awesome) | recruiting | Phase 2 | 760 | Hunan Province Tumor HospitalOTHER | 1 | Jun 7, 2024 | clinicaltrials |
| NCT06445881 | Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment(MSJZT-NSCLC) | recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04322617 | Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer(ATHENA) | recruiting | Phase 2 / Phase 3 | 1,200 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06440954 | Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases(EPIC) | recruiting | Phase 2 | 220 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05266846 | Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK(BEYOND) | recruiting | Phase 2 | 78 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT05584267 | Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy | recruiting | Phase 2 | 140 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06109558 | The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC(PROFILE) | recruiting | Phase 1 / Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06256237 | Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial | recruiting | Phase 2 | 30 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT04865250 | Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC(iReP) | recruiting | Phase 2 | 20 | University Hospital HeidelbergOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06418087 | Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)(DUPLE) | recruiting | Phase 2 | 49 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06363734 | Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial | recruiting | Phase 2 | 32 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06223711 | Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC | recruiting | Phase 2 | 43 | Universität des SaarlandesOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT05377658 | AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer | recruiting | Phase 2 | 43 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06241807 | Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC | recruiting | Phase 2 | 30 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06243003 | WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases | recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05011487 | Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC(NOCE01) | recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06177925 | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | recruiting | Phase 2 | 62 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06147570 | A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | recruiting | Phase 2 | 62 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT05344209 | Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer(LUNGVAC) | recruiting | Phase 2 | 138 | Vestre Viken Hospital TrustOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06092086 | Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC | recruiting | Phase 2 | 126 | Guangdong Association of Clinical TrialsOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05241028 | Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer | recruiting | Phase 2 | 80 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05777278 | Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression | recruiting | Phase 1 / Phase 2 | 29 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04728724 | Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer | recruiting | Phase 2 | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05841472 | Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 2 | 60 | CrystalGenomics, Inc.INDUSTRY | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06001151 | Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative(ACHELOUS) | recruiting | Phase 2 | 49 | Qian ChuOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05623267 | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT(SURPASS) | recruiting | Phase 2 / Phase 3 | 346 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05837052 | A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC | recruiting | Phase 2 | 49 | Zhejiang UniversityOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05940532 | A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC | recruiting | Phase 2 | 41 | Hunan Cancer HospitalOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05913089 | A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer | recruiting | Phase 2 | 58 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04539977 | PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer | recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02448992 | Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 90 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05271916 | First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations | recruiting | Phase 1 / Phase 2 | 140 | Shanghai Chest HospitalOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05800340 | Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | recruiting | Phase 2 | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05286957 | MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC(Seagull) | recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05686434 | Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) | recruiting | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05334277 | Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA(FOCUS-C) | recruiting | Phase 2 | 280 | Sun Yat-sen UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04875585 | Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC(INNWOP1) | recruiting | Phase 2 | 33 | Medical University InnsbruckOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05503667 | Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma | recruiting | Phase 2 | 96 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05469022 | Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy | recruiting | Phase 2 | 40 | Konkuk University Medical CenterOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05104788 | A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer(NeoIpower) | recruiting | Phase 2 | 27 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT03392233 | Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors | recruiting | Phase 2 | 100 | RenJi HospitalOTHER | 1 | Jan 5, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jul 3, 2024source: clinicaltrials